Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)


Options:
A: Arm Label: A1 (any SABA and/or SAMA); Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium, Drug: SABA, Drug: SAMA | Arm Label: A2 (glycopyrronium); Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium, Drug: SABA, Drug: LABA, Drug: SAMA | Arm Label: B1 (any LAMA or LABA and mMRC=1); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: Indacaterol maleate and glycopyrronium bromide, Drug: LAMA, Drug: ICS | Arm Label: B2 (glycopyrronium and mMRC=1); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: Indacaterol maleate and glycopyrronium bromide, Drug: LAMA | Arm Label: C1 (any LABA and ICS); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: ICS | Arm Label: C2 (indacaterol/glycopyrronium); Type: EXPERIMENTAL; Interventions: Drug: LABA, Drug: ICS | Arm Label: D1 (any LAMA or LABA and mMRC>1); Type: EXPERIMENTAL; Interventions: Drug: LAMA | Arm Label: D2 (indacaterol/glycopyrronium and mMRC>1); Type: EXPERIMENTAL; Interventions: Drug: LAMA | Intervention Type: DRUG; Name: Glycopyrronium; Assigned to Arm(s): A1 (any SABA and/or SAMA), A2 (glycopyrronium) | Intervention Type: DRUG; Name: SABA; Assigned to Arm(s): A1 (any SABA and/or SAMA), A2 (glycopyrronium) | Intervention Type: DRUG; Name: LABA; Assigned to Arm(s): A2 (glycopyrronium), B1 (any LAMA or LABA and mMRC=1), B2 (glycopyrronium and mMRC=1), C1 (any LABA and ICS), C2 (indacaterol/glycopyrronium) | Intervention Type: DRUG; Name: Indacaterol maleate and glycopyrronium bromide; Assigned to Arm(s): B1 (any LAMA or LABA and mMRC=1), B2 (glycopyrronium and mMRC=1) | Intervention Type: DRUG; Name: LAMA; Assigned to Arm(s): B1 (any LAMA or LABA and mMRC=1), B2 (glycopyrronium and mMRC=1), D1 (any LAMA or LABA and mMRC>1), D2 (indacaterol/glycopyrronium and mMRC>1) | Intervention Type: DRUG; Name: SAMA; Assigned to Arm(s): A1 (any SABA and/or SAMA), A2 (glycopyrronium) | Intervention Type: DRUG; Name: ICS; Assigned to Arm(s): B1 (any LAMA or LABA and mMRC=1), C1 (any LABA and ICS), C2 (indacaterol/glycopyrronium)
B: Arm Label: Aclidinium Bromide / Formoterol Fumarate; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide / Formoterol Fumarate | Arm Label: Salmeterol / Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone | Intervention Type: DRUG; Name: Aclidinium Bromide / Formoterol Fumarate; Assigned to Arm(s): Aclidinium Bromide / Formoterol Fumarate | Intervention Type: DRUG; Name: Salmeterol / Fluticasone; Assigned to Arm(s): Salmeterol / Fluticasone propionate
C: Arm Label: BGF (PT010) MDI 320/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/14.4/9.6 μg | Arm Label: BGF (PT010) MDI 160/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 160/14.4/9.6 μg | Arm Label: BFF (PT009) MDI 320/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BFF MDI 320/9.6 μg | Arm Label: GFF (PT003) MDI 14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: GFF MDI 14.4/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 320/14.4/9.6 μg; Assigned to Arm(s): BGF (PT010) MDI 320/14.4/9.6 μg | Intervention Type: DRUG; Name: GFF MDI 14.4/9.6 μg; Assigned to Arm(s): GFF (PT003) MDI 14.4/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 160/14.4/9.6 μg; Assigned to Arm(s): BGF (PT010) MDI 160/14.4/9.6 μg | Intervention Type: DRUG; Name: BFF MDI 320/9.6 μg; Assigned to Arm(s): BFF (PT009) MDI 320/9.6 μg
D: Arm Label: UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm; Type: EXPERIMENTAL; Interventions: Drug: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, Drug: Placebo DISKUS | Arm Label: FSC via ACCUHALER/DISKUS + placebo NDPI arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Drug: Placebo NDPI | Intervention Type: DRUG; Name: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI; Assigned to Arm(s): UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm | Intervention Type: DRUG; Name: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS; Assigned to Arm(s): FSC via ACCUHALER/DISKUS + placebo NDPI arm | Intervention Type: DRUG; Name: Placebo DISKUS; Assigned to Arm(s): UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm | Intervention Type: DRUG; Name: Placebo NDPI; Assigned to Arm(s): FSC via ACCUHALER/DISKUS + placebo NDPI arm

Answer: B